AUPH - Analysis shows benefit of Aurinia lupus drug over two years

An interim analysis of Aurinia Pharmaceuticals' (AUPH) LUPKYNIS (voclosporin) for lupus sustained meaningful reductions in proteinuria with no change in mean estimated glomerular filtration rate at 104 weeks of treatment.The analysis of 216 blinded subjects found that proteinuria continued to improve with a greater reduction in urine protein creatinine ratio from pre-treatment baseline to year two in the voclosporin arm compared to the control (-3.1 vs -2.1 mg/mg).Also, a greater reduction in proteinuria between arms was also observed between one and two years (1.0 vs 0.6 mg/mg).The results will be presented at the European Alliance of Associations for Rheumatology 2021 Congress next month.Aurinia shares are up 2.2% to $13.10 in after-hours trading.

For further details see:

Analysis shows benefit of Aurinia lupus drug over two years